GRAIL today announced a collaboration with global biopharmaceutical companies Amgen, AstraZeneca, and Bristol Myers Squibb to evaluate GRAIL’s methylation-based technology for the detection of minimal residual disease (MRD). Cancer MRD testing is used in clinical and research applications to detect the presence or absence of … Continue reading GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease